Optinose - OPTN Net Sales Margin

Optinose - graphic logo of issuer OPTN

The expansion of XHANCE commercial reach in treating rhinosinusitis drives momentum where the net profit margin visualizes the business's actual yield for OptiNose, Inc. (OPTN). The EDS system and XHANCE device ensure deep drug penetration into the sinuses, while integration with anti-polyp agents establishes a standard for ENT therapy. The value of -36.60 represents the current metric, allowing a distinction between a sustainable profitability trend and random spikes.

OptiNose, Inc. (OPTN) Net Return on Sales: for the period 07/04/2022 - 05/31/2025

Summary analytical data breakdowns for Optinose (OPTN)

- share price and consensus valuation forecast:
Comprehensive company analysis:OptiNose, OPTN
Manufactured product of OptiNose Inc

Identifying sustainable assets requires separating long-term trends from market noise. Net profit margin measures the portion of profit remaining from every dollar of revenue after all expenses. For OptiNose, Inc. (OPTN), this calculation demonstrates the efficiency of commercializing drug delivery systems amid growing demand for rhinosinusitis treatment. Positive momentum in the net profit margin confirms the scalability of the business model. Investors should use this chart to assess the operational resilience of the issuer.

Who OptiNose, Inc. competes with

HLN: Net Sales Margin|Net Return on Sales KVUE|Net Margin veronapharma.com|Net Return on Sales MENS (Jyong Biotech Corp)|Net Margin Ligand (LGND)|Net Sales Margin amneal.com (AMRX)|Net Sales Margin PRGO (perrigo.com)|Alvotech SA (ALVO) - Net Margin|Liquidia Inc. - Net Sales Margin|Net Profitability Margin Galapagos Corp (GLPG)|ANI Pharmaceuticals (ANIP) - Net Margin|Net Return on Sales MNKD|Net Margin Amphastar Pharmaceuticals, Inc.|Pacira Pharmaceuticals (PCRX) - Company Sales Margin|Net Sales Margin SPRY|TBPH - Net Margin|Aquestive Pharma - Return on Sales by Net Profit|Net Sales Margin scpharmaceuticals.com SCPH|Tectonic - Net Sales Margin|TNXP - Net Sales Margin|SXTC: Net Sales Margin|Eupraxia Pharma - Net Profit Rate|BHST (bioharvest.com) - Net Sales Margin|Net Return on Sales EXOZ (invizyne.com)|Net Sales Margin ORMP|Company Sales Margin Entera Bio|Net Sales Margin HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma - Net Margin|Cumberland Corp - Net Sales Margin|QNTM - Net Sales Margin|FibroGen, Inc. (FGEN) - Net Margin|TELO: Company Net Profitability|RANI (Rani Therapeutics Inc) - Net Sales Margin|Net Margin synergychc.com SNYR|Net Margin Rallybio Corp. (RLYB)|LEXX - Net Margin|Net Sales Margin PULM (pulmatrix.com)|Company Net Profitability PTHL (Pheton)|APM - Net Margin|Company Sales Margin Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Net Margin|TNF Pharma (TNFA) - Net Sales Margin|YCBD (cbdmd.com) - Net Sales Margin|Return on Sales by Net Profit PainReform (PRFX)|Net Margin Altamira Therapeutics (CYTO)|Company Sales Margin Lipella Pharma|Net Margin pieris.com PIRS|Net Profit Rate PROC|PTPI - Net Margin|Qilian International Holding (QLI) - Return on Sales by Net Profit|SLRN: Net Sales Margin|Return on Sales by Net Profit TFF Pharma